| Alpha-2C Adrenergic Receptor | |
|---|---|
| Protein Name | Alpha-2C adrenergic receptor |
| Gene | ADRA2C |
| UniProt | [P08913](https://www.uniprot.org/uniprotkb/P08913) |
| Protein Class | G-protein coupled receptor (GPCR) |
| Localization | Cell membrane; presynaptic terminals |
| Major Pathway | [Adrenergic Signaling](/mechanisms/adrenergic-signaling) |
ADRA2C encodes the alpha-2C adrenergic receptor (α2C-AR), one of three alpha-2 adrenergic receptor subtypes (α2A, α2B, α2C) that belong to the G protein-coupled receptor (GPCR) superfamily. The α2C-AR is distinguished by its unique anatomical distribution, particularly in the central nervous system, and its role in modulating neurotransmitter release under basal and stressed conditions[1][2].
Unlike the α2A and α2B subtypes, which are widely expressed throughout the brain and peripheral tissues, the α2C-AR exhibits a more restricted distribution with particularly high expression in regions involved in motor control and autonomic function. This distribution pattern has made it a focus of interest in neurodegenerative disease research[3][4].
The ADRA2C receptor is a 461 amino acid GPCR with characteristic seven-transmembrane domain architecture. It shares structural features with other alpha-2 adrenergic receptors but exhibits distinct pharmacological properties:
Alpha-2 adrenergic receptors are activated by endogenous catecholamines including norepinephrine (noradrenaline) and epinephrine (adrenaline), as well as by synthetic agonists such as clonidine and dexmedetomidine. The α2C-AR has distinct pharmacological profiles:
The receptor exhibits constitutive (agonist-independent) activity, and its signaling can be modulated by inverse agonists that reduce basal signaling below baseline levels.
The α2C-AR has a distinctive distribution pattern in the brain[2:1]:
Lower expression in peripheral organs:
The α2C-AR plays a critical role in presynaptic regulation of neurotransmitter release:
The receptor is Particularly important in modulating stress responses:
ADRA2C is expressed in glial cells and modulates their function[5]:
The noradrenergic system is prominently affected in Alzheimer's disease, and ADRA2C has been implicated in disease pathogenesis[6][7]:
The α2C-AR, along with α2A-AR, represents a therapeutic target for enhancing cognitive function in AD through modulation of norepinephrine signaling.
ADRA2C has emerged as particularly relevant in Parkinson's disease[4:1][8][9]:
Genetic deletion of ADRA2C in alpha-synuclein transgenic mice results in modified disease progression, suggesting a role in disease pathogenesis[8:1].
The α2C-AR represents a compelling therapeutic target for several reasons[10][7:1]:
Several strategies are being explored:
The noradrenergic and dopaminergic systems are closely linked:
Tansey MG, et al. Alpha2-adrenergic receptor-mediated modulation of microglial activation and neurodegeneration. Brain Research. 2002. ↩︎
Culver KE, et al. Regional distribution and biochemical analysis of the alpha2C adrenergic receptor in the human brain. Journal of Neural Transmission. 2001. ↩︎ ↩︎
Schmitt H, et al. The role of alpha-adrenoceptors in neurodegenerative diseases. Autonomic Neuroscience. 2003. ↩︎
Rommelfanger KS, et al. Alpha-synuclein and the norepinephrine system: implications for Parkinson's disease. Experimental Neurology. 2007. ↩︎ ↩︎
Gibson LC, et al. Norepinephrine and alpha2C-adrenoceptor signaling in glia. Glia. 2016. ↩︎
Manaye S, et al. Norepinephrine and alpha-adrenoceptor expression in Alzheimer's disease. Brain Pathology. 2017. ↩︎
Espay AJ, et al. Alpha2-agtonists in Parkinson's disease: neuroprotection through adrenergic modulation. Nature Reviews Neurology. 2014. ↩︎ ↩︎
Henning MS, et al. Alpha2C-adrenoceptor deficiency modifies the progression of alpha-synuclein pathology. Neurobiology of Disease. 2019. ↩︎ ↩︎
Chiang MC, et al. Alpha2C-adrenoceptor blockade attenuates neuroinflammation in models of Parkinson's disease. Journal of Neuroinflammation. 2019. ↩︎
Vasudevan JT, et al. Alpha2-adrenergic receptors in neuroprotection. CNS Drugs. 2001. ↩︎